Shares of Catalyst Biosciences, Inc. (NASDAQ:CBIO) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $3.50 and last traded at $3.51, with a volume of 42,581 shares changing hands. The stock had previously closed at $3.69.

CBIO has been the topic of a number of recent research reports. Zacks Investment Research downgraded Catalyst Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, June 5th. Chardan Capital initiated coverage on Catalyst Biosciences in a report on Monday, June 12th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Ladenburg Thalmann Financial Services initiated coverage on Catalyst Biosciences in a report on Tuesday, June 6th. They set a “buy” rating and a $11.00 price objective for the company.

The company’s market capitalization is $14.70 million. The stock has a 50-day moving average of $4.32 and a 200 day moving average of $5.56.

Catalyst Biosciences (NASDAQ:CBIO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.46) by $1.07. Catalyst Biosciences had a negative return on equity of 92.61% and a negative net margin of 3,127.92%. The company had revenue of $0.11 million for the quarter. Analysts predict that Catalyst Biosciences, Inc. will post ($5.76) EPS for the current fiscal year.

An institutional investor recently bought a new position in Catalyst Biosciences stock. Bank of New York Mellon Corp acquired a new position in Catalyst Biosciences, Inc. (NASDAQ:CBIO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 22,891 shares of the biopharmaceutical company’s stock, valued at approximately $107,000. Bank of New York Mellon Corp owned approximately 0.54% of Catalyst Biosciences as of its most recent SEC filing. Institutional investors and hedge funds own 5.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Catalyst Biosciences, Inc. (NASDAQ:CBIO) Hits New 12-Month Low at $3.50” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Receive News & Ratings for Catalyst Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc. and related companies with's FREE daily email newsletter.